Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRME Prime Medicine, Inc.

Post-Mkt 08-11 16:59:32 EDT

3.26

+0.11

+3.49%

盘后3.25

-0.01-0.28%

16:56 EDT

High3.29	Low3.09	Vol2.25M
Open3.20	D1 Closing3.15	Amplitude6.51%
Mkt Cap588.46M	Tradable Cap371.64M	Total Shares180.51M
T/O7.23M	T/O Rate1.97%	Tradable Shares114.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":3.26,"timestamp":1786478400000,"preClose":3.15,"halted":0,"volume":2250059,"hourTrading":{"tag":"盘后","latestPrice":3.2509,"preClose":3.26,"latestTime":"16:56 EDT","volume":21227,"amount":69174.0530109,"timestamp":1786481770888,"change":-0.0091,"changeRate":-0.002791,"amplitude":0.015337},"delay":0,"changeRate":0.03492063492063488,"floatShares":113999999,"shares":180510658,"eps":-1.085332,"marketStatus":"Post-Mkt","change":0.11,"latestTime":"08-11 16:59:32 EDT","open":3.2,"high":3.29,"low":3.085,"amount":7233742.1298198,"amplitude":0.065079,"askPrice":3.28,"askSize":2600,"bidPrice":3.25,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.085332,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1786492800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":3.15,"preHourTrading":{"tag":"盘前","latestPrice":3.21,"preClose":3.15,"latestTime":"09:28 EDT","volume":14441,"amount":46341.2628665,"timestamp":1786454880036,"change":0.06,"changeRate":0.019048,"amplitude":0.012698},"postHourTrading":{"tag":"盘后","latestPrice":3.2509,"preClose":3.26,"latestTime":"16:56 EDT","volume":21227,"amount":69174.0530109,"timestamp":1786481770888,"change":-0.0091,"changeRate":-0.002791,"amplitude":0.015337},"volumeRatio":0.779434,"impliedVol":0.8334,"impliedVolPercentile":0.2112},"requestUrl":"/m/hq/s/PRME/tweets","defaultTab":"tweets","newsList":[{"id":"2658075987","title":"Prime Medicine Price Target Maintained with a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2658075987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658075987?lang=en_us&edition=fundamental","pubTime":"2026-08-10 18:35","pubTimestamp":1786358100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657661357","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Cresco Labs (OtherCRLBF), Prime Medicine, Inc. (PRME) and Steris (STE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657661357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657661357?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:30","pubTimestamp":1786055431,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cresco Labs (CRLBF), Prime Medicine, Inc. (PRME) and Steris (STE)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cresco-labs-othercrlbf-prime-medicine-inc-prme-and-steris-ste-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cresco-labs-othercrlbf-prime-medicine-inc-prme-and-steris-ste-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1892829315.USD","LU0289961442.SGD","LU0128526141.USD","BK4137","HCSG","BK4581","LU0472753341.HKD","BK4082","LU0689626769.HKD","LU0029874061.USD","BK4139","CRLBF","LU0511384066.AUD","STE","LU0057025933.USD","XBI","BK4588","LU0124676726.USD","LU0289739343.SGD","PRME","BK4585","LU0069063385.USD","BK4007","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657965099","title":"NextCure Q2 Net Loss Narrows on Lower Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657965099","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657965099?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:16","pubTimestamp":1786047402,"startTime":"0","endTime":"0","summary":"NextCure Q2 net loss narrows on lower expensesOverviewU.S. cancer drug developer's Q2 net loss narrowed yr/yr on lower R&D and admin costsCompany announced proposed merger with Avere Therapeutics, exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALXO","PRME","TRDA","NXTC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657665749","title":"INmune Bio Q2 Net Loss Narrows on Lower Impairment Charges","url":"https://stock-news.laohu8.com/highlight/detail?id=2657665749","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657665749?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:09","pubTimestamp":1786046981,"startTime":"0","endTime":"0","summary":"INmune Bio Q2 net loss narrows on lower impairment chargesOverviewUS biotechnology firm's Q2 net loss narrowed sharply from prior yearCompany reported no revenue for the quarterQ2 results benefited fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALXO","PRME","BK4583","EBS","INMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657658045","title":"Prime Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657658045","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657658045?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:07","pubTimestamp":1786028851,"startTime":"0","endTime":"0","summary":"Prime Medicine, Inc. reports results for the quarter ended June 30 - Earnings SummaryPrime Medicine, Inc.PRME.OQreported a quarterly adjusted loss of 24 cents per share for the quarter ended June 30, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4432HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639105","title":"Prime Medicine Publishes Corporate Presentation on Prime Editing Platform, Liver Disease Pipeline Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639105","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639105?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:20","pubTimestamp":1786018846,"startTime":"0","endTime":"0","summary":"Prime Medicine publishes corporate presentation on prime editing platform, liver disease pipeline focusPrime Medicine highlighted a near-term focus on in vivo liver programs, led by Wilson disease can","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbrmPs0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639522","title":"Prime Medicine, Inc. Q2 EPS USD -0.24","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639522","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639522?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:13","pubTimestamp":1786018417,"startTime":"0","endTime":"0","summary":"Aug 06 (Reuters) - Prime Medicine, Inc. Q2 operating expenses USD 44.439 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 06-AUG-202612:01:02.427 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nRSDw0yDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657367546","title":"Prime Medicine Q2 FY26 Net Loss Narrows to $42.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657367546","media":"Reuters","labels":["policyRegulatory","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657367546?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:04","pubTimestamp":1786017850,"startTime":"0","endTime":"0","summary":"Prime Medicine Q2 FY26 net loss narrows to $42.1 millionPrime Medicine posted a net loss of USD 42.1 million for Q2 2026, narrowing from USD 52.6 million a year earlier.R&D expense fell 19.32% to USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL7VRXWs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657947636","title":"Prime Medicine Q2 EPS $(0.24) Beats $(0.26) Estimate, Sales $1.154M Miss $1.295M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657947636","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657947636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:01","pubTimestamp":1786017719,"startTime":"0","endTime":"0","summary":"Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 41.46 percent increase over losses of $(0.41) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60991240/prime-medicine-q2-eps-0-24-beats-0-26-estimate-sales-1-154m-miss-1-295m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657963672","title":"Press Release: Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657963672","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657963672?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:01","pubTimestamp":1786017660,"startTime":"0","endTime":"0","summary":"-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","WD","VEGI","LU0345781412.USD","LU0345780950.USD","SDMF","BK4093","LU0630314457.HKD","BK4139","ISMF","JPFP","TFPN","BK4229","BK4588","PRME","IND","BK4195","BK4585","LABU","CF","DBMF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636504","title":"Prime Medicine, Inc. Q2 Income from Operations USD -43.285 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636504?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXR4JX5D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657634342","title":"Prime Medicine, Inc: Expects Cash and Investments as of June 30, 2026 Sufficient to Fund Operations into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2657634342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657634342?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXR4JX5D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655744805","title":"Scribe's Genetic Editing Aims to Prevent Heart Attacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2655744805","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655744805?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:26","pubTimestamp":1785421560,"startTime":"0","endTime":"0","summary":"Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe's one-time treatments can halv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPH","BEAM","LU0689626769.HKD","LU1023059063.AUD","IE00BJT1NW94.SGD","IHE","IXJ","FHLC","IE00BN8TJ469.HKD","BK4007","LU1035773651.USD","TRUH","IE00BBT3K403.USD","LU0942090050.USD","LU2360032135.SGD","PAWZ","MRK","ARKG","LU2361044865.SGD","LU1861558580.USD","LU1430594728.SGD","LU0238689110.USD","SCTX","LU1941712264.USD","LU2125909247.SGD","CRSP","JDOC","IYH","XLV","IE0009355771.USD","LU1162221912.USD","HRTS","SG9999014575.USD","VHT","LU0203347892.USD","SG9999014559.SGD","PRME","IE00B4R5TH58.HKD","LU0006306889.USD","LU2112291526.USD","LU2433249047.HKD","LU0058720904.USD","LU1066051225.USD","RXL","BK4534","LU1066053197.SGD","FTXH","LU1201861249.SGD","LU1861559042.SGD","LU2023250843.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653773740","title":"Prime Medicine Says FDA Clears IND for Pm577a in Wilson Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653773740","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653773740?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:13","pubTimestamp":1784837601,"startTime":"0","endTime":"0","summary":"Prime Medicine says FDA clears IND for PM577a in Wilson disease trialPrime Medicine won FDA clearance of its IND for PM577a, an in vivo prime editor targeting H1069Q-mutated Wilson disease.The decisio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL53jTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4112","IE00BN0W2V16.EUR","LU2210149790.SGD","NDAQ","BK4585","BK4588","IE00BGHQF748.EUR","BK4139","PRME","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD","BCDF","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653773682","title":"Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for Pm577a in H1069q-mutated Wilson Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2653773682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653773682?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:05","pubTimestamp":1784837100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA4PNN00:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653077366","title":"Prime Medicine, - Phase 1/2 Trial for Pm577a Expected to Start in H2 2026 with Initial Data in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2653077366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653077366?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:05","pubTimestamp":1784837100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA4PNN00:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650159219","title":"LifeSci Capital Remains a Buy on Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2650159219","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650159219?lang=en_us&edition=fundamental","pubTime":"2026-07-11 22:35","pubTimestamp":1783780516,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $6.00. According to Ti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lifesci-capital-remains-a-buy-on-prime-medicine-inc-prme-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650139100","title":"Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2650139100","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650139100?lang=en_us&edition=fundamental","pubTime":"2026-07-10 23:52","pubTimestamp":1783698720,"startTime":"0","endTime":"0","summary":"Prime Medicine, Inc.  is currently at $3.64, down $0.59 or 13.83%--Would be lowest close since June 26, 2026, when it closed at $3.43--On pace for largest percent decrease since May 19, 2025, when it fell 16.04%--Currently down two consecutive days; down 21.1% over this period--Worst two day stretch since the two days ending May 20, 2025, when it fell 26.1%--Down 5.81% this week; worst weekly performance since the week ending June 12, 2026, when it fell 9.31%--Down 1.22% month-to-date--Up 5.04% year-to-date--Down 82.74% from its all-time closing high of $21.12 on Nov. 11, 2022--Down 16.21% from 52 weeks ago , when it closed at $4.35--Down 45.35% from its 52-week closing high of $6.67 on Oct. 2, 2025--Up 35% from its 52-week closing low of $2.70 on May 19, 2026--Traded as low as $3.62; lowest intraday level since July 1, 2026, when it hit $3.61--Down 14.42% at today's intraday low; largest intraday percent decrease since June 5, 2026, when it fell as much as 15.27%All data as of 11:49:1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650693990","title":"TD Cowen says arbitration decision removes overhang for Prime Medicine’s PM647","url":"https://stock-news.laohu8.com/highlight/detail?id=2650693990","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650693990?lang=en_us&edition=fundamental","pubTime":"2026-07-09 00:45","pubTimestamp":1783529110,"startTime":"0","endTime":"0","summary":"TD Cowen notes that Prime Medicine (PRME) announced a positive binding arbitration resolution with Beam Therapeutics (BEAM) over PM647 in alpha-1 a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/td-cowen-says-arbitration-decision-removes-overhang-for-prime-medicines-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/td-cowen-says-arbitration-decision-removes-overhang-for-prime-medicines-pm647-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4611","GSIB","PRME","BK4127","BK4566","BK4588","LU1861559042.SGD","BK4139","BEAM","COWN","BK4556","LU1861558580.USD","TD","BK4585","BK4535","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650997531","title":"Resolution in favor of Prime has limited impact to Beam, says BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2650997531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650997531?lang=en_us&edition=fundamental","pubTime":"2026-07-08 23:45","pubTimestamp":1783525515,"startTime":"0","endTime":"0","summary":"BofA analyst Alec Stranahan reiterated a Buy rating and $47 price target on Beam Therapeutics (BEAM) after Prime Medicine (PRME) announced a “posit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/resolution-in-favor-of-prime-has-limited-impact-to-beam-says-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/resolution-in-favor-of-prime-has-limited-impact-to-beam-says-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4585","BK4139","LU1861558580.USD","BEAM","LU1861559042.SGD","BK4588","BK4556","BK4611","BK4535","PRME"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com;investors.primemedicine.com","stockEarnings":[{"period":"1week","weight":0.121},{"period":"1month","weight":-0.1667},{"period":"3month","weight":-0.0455},{"period":"6month","weight":-0.087},{"period":"1year","weight":-0.1678},{"period":"ytd","weight":-0.0922}],"compareEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":0.0239},{"period":"3month","weight":0.0472},{"period":"6month","weight":0.1172},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1336}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070058},{"month":2,"riseRate":0.5,"avgChangeRate":0.101559},{"month":3,"riseRate":0,"avgChangeRate":-0.224329},{"month":4,"riseRate":0.5,"avgChangeRate":-0.072402},{"month":5,"riseRate":0.5,"avgChangeRate":-0.000767},{"month":6,"riseRate":0.75,"avgChangeRate":0.248413},{"month":7,"riseRate":0.75,"avgChangeRate":0.106402},{"month":8,"riseRate":0.25,"avgChangeRate":-0.103358},{"month":9,"riseRate":0.333333,"avgChangeRate":0.111542},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.141809},{"month":11,"riseRate":0.25,"avgChangeRate":-0.086687},{"month":12,"riseRate":0.5,"avgChangeRate":0.02429}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}